Aeterna Zentaris (AEZS) Competitors $2.83 +0.01 (+0.31%) As of 04/17/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock AEZS vs. OVID, MTEX, RNXT, CDIO, PULM, CVM, ENLV, NAII, PMN, and NNVCShould you be buying Aeterna Zentaris stock or one of its competitors? The main competitors of Aeterna Zentaris include Ovid Therapeutics (OVID), Mannatech (MTEX), RenovoRx (RNXT), Cardio Diagnostics (CDIO), Pulmatrix (PULM), CEL-SCI (CVM), Enlivex Therapeutics (ENLV), Natural Alternatives International (NAII), ProMIS Neurosciences (PMN), and NanoViricides (NNVC). These companies are all part of the "pharmaceutical products" industry. Aeterna Zentaris vs. Ovid Therapeutics Mannatech RenovoRx Cardio Diagnostics Pulmatrix CEL-SCI Enlivex Therapeutics Natural Alternatives International ProMIS Neurosciences NanoViricides Aeterna Zentaris (NASDAQ:AEZS) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, community ranking, media sentiment, dividends, risk, profitability and institutional ownership. Do analysts prefer AEZS or OVID? Ovid Therapeutics has a consensus price target of $3.03, indicating a potential upside of 951.05%. Given Ovid Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Ovid Therapeutics is more favorable than Aeterna Zentaris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aeterna Zentaris 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Ovid Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media favor AEZS or OVID? In the previous week, Aeterna Zentaris' average media sentiment score of 0.00 equaled Ovid Therapeutics'average media sentiment score. Company Overall Sentiment Aeterna Zentaris Neutral Ovid Therapeutics Neutral Which has more volatility & risk, AEZS or OVID? Aeterna Zentaris has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500. Which has better earnings and valuation, AEZS or OVID? Aeterna Zentaris has higher revenue and earnings than Ovid Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Aeterna Zentaris, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAeterna Zentaris$2.37M2.14-$16.55M-$14.86-0.19Ovid Therapeutics$566K36.24-$52.34M-$0.38-0.76 Is AEZS or OVID more profitable? Aeterna Zentaris has a net margin of -760.32% compared to Ovid Therapeutics' net margin of -5,142.56%. Ovid Therapeutics' return on equity of -39.24% beat Aeterna Zentaris' return on equity.Company Net Margins Return on Equity Return on Assets Aeterna Zentaris-760.32% -83.45% -45.76% Ovid Therapeutics -5,142.56%-39.24%-26.19% Do institutionals and insiders believe in AEZS or OVID? 0.7% of Aeterna Zentaris shares are held by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are held by institutional investors. 0.1% of Aeterna Zentaris shares are held by insiders. Comparatively, 13.3% of Ovid Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community prefer AEZS or OVID? Aeterna Zentaris received 62 more outperform votes than Ovid Therapeutics when rated by MarketBeat users. However, 70.97% of users gave Ovid Therapeutics an outperform vote while only 58.60% of users gave Aeterna Zentaris an outperform vote. CompanyUnderperformOutperformAeterna ZentarisOutperform Votes41958.60% Underperform Votes29641.40% Ovid TherapeuticsOutperform Votes35770.97% Underperform Votes14629.03% SummaryOvid Therapeutics beats Aeterna Zentaris on 11 of the 17 factors compared between the two stocks. Get Aeterna Zentaris News Delivered to You Automatically Sign up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AEZS vs. The Competition Export to ExcelMetricAeterna ZentarisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.26M$6.44B$5.30B$7.34BDividend YieldN/A3.23%5.12%4.30%P/E Ratio-0.196.8921.8617.80Price / Sales2.14230.57380.5497.75Price / CashN/A65.6738.2634.64Price / Book0.195.936.453.98Net Income-$16.55M$142.99M$3.22B$247.81M7 Day Performance0.84%4.43%2.85%1.80%1 Month Performance-11.05%-12.72%-8.67%-6.81%1 Year Performance-63.86%-9.42%11.46%1.31% Aeterna Zentaris Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AEZSAeterna ZentarisN/A$2.83+0.3%N/A-63.9%$10.26M$2.37M-0.1920Analyst ForecastOVIDOvid Therapeutics4.1423 of 5 stars$0.29+2.5%$3.03+956.9%-91.0%$20.40M$566,000.00-0.6160Gap UpMTEXMannatech1.2911 of 5 stars$10.68+7.2%N/A+20.1%$20.30M$117.87M-13.19250Analyst ForecastGap UpRNXTRenovoRx2.0351 of 5 stars$0.84+9.4%$6.00+610.2%-16.4%$20.28M$43,000.00-1.486Short Interest ↑News CoverageGap DownHigh Trading VolumeCDIOCardio Diagnostics1.8176 of 5 stars$0.39-4.1%$2.00+414.8%-64.2%$20.26M$34,890.000.001Short Interest ↑Negative NewsPULMPulmatrixN/A$5.39-0.2%N/A+224.1%$19.67M$7.81M-2.0420Gap DownCVMCEL-SCIN/A$0.24-21.9%N/A-83.2%$19.16MN/A-0.5043Gap UpHigh Trading VolumeENLVEnlivex Therapeutics3.2829 of 5 stars$0.89-1.3%$10.00+1,028.4%-38.2%$18.97MN/A-0.9070Short Interest ↓NAIINatural Alternatives International1.2916 of 5 stars$3.04+3.1%N/A-59.0%$18.85M$121.85M-2.36290Analyst ForecastShort Interest ↓Gap UpHigh Trading VolumePMNProMIS Neurosciences2.8742 of 5 stars$0.57+2.6%$6.00+944.6%-67.8%$18.78MN/A-5.745NNVCNanoViricidesN/A$1.19+7.2%N/A+13.7%$18.61MN/A-1.6520Positive NewsGap Down Related Companies and Tools Related Companies OVID Alternatives MTEX Alternatives RNXT Alternatives CDIO Alternatives PULM Alternatives CVM Alternatives ENLV Alternatives NAII Alternatives PMN Alternatives NNVC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AEZS) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aeterna Zentaris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aeterna Zentaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AEZS Stock Free AEZS Stock Alerts